Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

Pages

9131 items
11:45 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Scars/wrinkles Patient sample and mouse studies suggest inhibiting CXCL12 could help treat scars. In injured skin samples from scar patients, CXCL12 levels were higher in patients aged 40 years or younger with thick scars than...
11:45 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Patient sample, cell culture and mouse studies suggest inhibiting CB1 could help treat Duchenne muscular dystrophy (DMD). In quadriceps tissue samples from pediatric DMD patients, CB1 expression levels were higher than in...
11:44 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting CASP1 could help treat AD. In primary human neurons overexpressing APP, a tool compound CASP1 inhibitor decreased axon degeneration compared with no treatment. In a...
11:43 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal; autoimmune disease

INDICATION: Osteoporosis; arthritis Mouse studies suggest inhibiting miR-182 could help treat osteoporosis and arthritis. In a mouse model of estrogen deficiency-induced osteoporosis, myeloid lineage osteoclast precursor-specific knockout of miR-182 or chitosan nanoparticles loaded with an antisense...
11:43 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than in...
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest the selective GABA re-uptake inhibitor tiagabine could help treat neonatal hypoxic brain injury. In a neonatal mouse model of hypoxia-induced brain injury, tiagabine decreased the percentage of missteps, a measure of...
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Cell culture and rat studies identified a pyrrolidine sulfonamide-based TRPV4 inhibitor that could help treat pulmonary edema associated with heart failure. Chemical synthesis and testing of pyrrolidine sulfonamide analogs in cell-based activity assays, followed...
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Endocrine/Metabolic; neurology

INDICATION: Porphyria; pain Mouse, rabbit and monkey studies suggest a lipid nanoparticle (LNP)-encapsulated mRNA encoding HMBS could help treat acute intermittent porphyria (AIP), which is caused by hepatic HMBS deficiency, and AIP-associated pain. In mouse...
11:40 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation

INDICATION: Asthma Rat studies suggest antagonizing TRPV1 or combined antagonism of its upstream activators LPAR1, LPAR2, LPAR3 and LPAR4 could help treat allergic asthma. In a rat model of allergic asthma, plasma levels of lysophosphatidic acid...
11:39 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Rat and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) NEAT1 could help treat neointimal hyperplasia. In carotid artery samples from a rat model of angioplasty-associated neointimal hyperplasia, NEAT1 levels were higher...

Pages